XML 68 R35.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Business Combinations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Standard BioTools |
Business Acquisition [Line Items] |
Schedule of the Acquisition-date Fair Value of Consideration Transferred | Purchase consideration also included replacement of equity awards attributable to pre-combination services. The acquisition-date fair value of consideration transferred in the Merger totaled approximately $444.2 million, comprising the following:
SomaLogic Common Stock issued and outstanding as of January 5, 2024 |  |  | 188,808 |
Fixed exchange ratio |  |  | 1.11 |
Shares of Standard BioTools common stock issued to SomaLogic stockholders |  |  | 209,577 |
Standard BioTools common stock price at close of Merger |  | $ | 2.00 |
Fair value of Standard BioTools common stock issued to SomaLogic stockholders |  | $ | 419,154 |
Fair value of Standard BioTools replacement equity awards attributable to pre-combination service |  |  | 26,923 |
Less: Fair value of restricted shares subject to service conditions |  |  | (1,858 | )
Total consideration transferred |  | $ | 444,219 |
Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed | The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date:
Total consideration |  | $ | 444,219 |
Assets acquired |  |  |
Cash and cash equivalents |  |  | 278,857 |
Short-term investments |  |  | 148,305 |
Accounts receivable |  |  | 16,430 |
Inventory |  |  | 14,642 |
Prepaid expenses and other current assets |  |  | 4,835 |
Property and equipment |  |  | 22,455 |
Non-current inventory |  |  | 12,208 |
Royalty receivable |  |  | 4,669 |
Operating lease right-of-use assets |  |  | 3,796 |
Other non-current assets |  |  | 1,590 |
Intangible Assets |  |  | 25,500 |
Total assets acquired |  |  | 533,287 |
Liabilities assumed |  |  |
Accounts payable and accrued liabilities |  |  | 20,660 |
Operating lease liabilities, current |  |  | 1,601 |
Deferred revenue, current |  |  | 3,522 |
Operating lease liabilities, non-current |  |  | 2,193 |
Deferred revenue, non-current |  |  | 30,667 |
Warrant liabilities |  |  | 906 |
Other non-current liabilities |  |  | 4,306 |
Total Liabilities |  |  | 63,855 |
Total fair value of net assets acquired |  | $ | 469,432 |
Gain on bargain purchase |  | $ | (25,213 | )
Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger | The valuation of the intangible assets acquired in connection with the Merger, along with their estimated useful lives, is as follows (in thousands):
|  | Fair Value |  |  | Weighted Average Useful Life (years) |
Developed technology |  | $ | 20,000 |  |  |  | 9.0 |
Trade name |  |  | 2,750 |  |  |  | 7.0 |
Customer relationships |  |  | 2,750 |  |  |  | 11.0 |
Total intangible assets |  | $ | 25,500 |  |  |  | 9.0 |
Schedule of Unaudited Pro Forma Financial Information | The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023.
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Revenue |  | $ | 175,077 |  |  | $ | 192,465 |
Net loss |  |  | (168,654 | ) |  |  | (164,280 | )
Sengenics |
Business Acquisition [Line Items] |
Schedule of Consideration Transferred to Sellers | ended December 31, 2024. The consideration transferred to the sellers of Sengenics comprised the following:
Standard BioTools Common Stock |  | $ | 5,878 |
Cash |  |  | 2,212 |
Contingent consideration |  |  | 5,600 |
Total consideration transferred |  | $ | 13,690 |
Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed | The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of November 21, 2024:
Total consideration |  | $ | 13,690 |
Assets acquired |  |  |
Cash and cash equivalents |  | $ | 828 |
Accounts receivable |  |  | 282 |
Inventory |  |  | 847 |
Property and equipment |  |  | 583 |
Intangible assets |  |  | 6,400 |
Prepaid expenses and other assets |  |  | 766 |
Total assets acquired |  |  | 9,706 |
Liabilities assumed |  |  |
Accounts payable and accrued liabilities |  |  | 658 |
Operating lease liabilities |  |  | 24 |
Deferred revenue |  |  | 419 |
Other liabilities |  |  | 25 |
Total Liabilities |  |  | 1,126 |
Total fair value of net assets acquired |  | $ | 8,580 |
Goodwill |  | $ | 5,110 |
Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger | The valuation of the intangible assets acquired, along with their estimated useful lives, is as follows (in thousands):
|  | Fair Value |  |  | Weighted Average Useful Life (years) |
Developed technology |  | $ | 5,800 |  |  |  | 9.0 |
Trade name |  |  | 500 |  |  |  | 7.0 |
Customer relationships |  |  | 100 |  |  |  | 11.0 |
Total intangible assets |  | $ | 6,400 |  |  |  | 8.9 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination. + References No definition available. + Details
Name: | us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lab_StandardBiotoolsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lab_SengenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |